Nabi Biopharmaceuticals has signed a definitive agreement to sell PentaStaph (Pentavalent S. aureus Vaccine) and related assets to GlaxoSmithKline for as much as $46 million. Nabi will receive an initial cash payment of $20 million upon closing and an additional $26 million based on four milestones. It is believed that the successful development of a vaccine against S. aureus is critical in the fight against Methicillin-resistant S. aureus (MRSA), an increasingly prevalent strain of the bacte...